Altimmune, Inc.
NASDAQ:ALTBiotechnology
+$0.08 today
- Market cap
- $297.72M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
Volume 4.25M
Average 3.81M
ALT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Altimmune, Inc.NASDAQ: ALT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $16.17M rose 2.2% year over year, ahead of the -12.8% change in trailing-twelve-month research & development. Sequentially, it fell 12.2% from the prior quarter. Over 3 fiscal years it compounded at -2.0% a year.
Context
- Research & development amounted to 162029.3% of revenue in FY2025, down 249100.7 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +2.2% holds above the trailing-twelve-month pace of -12.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 66.43M USD
- Year-over-year change
- -19.2%
- 4-year CAGR
- -2.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 66.43M | -19.2% |
| FY2024 | 2024-12-31 | 82.23M | +25.0% |
| FY2023 | 2023-12-31 | 65.8M | -6.7% |
| FY2022 | 2022-12-31 | 70.54M | -5.4% |
| FY2021 | 2021-12-31 | 74.54M | — |
Research & Development vs competitors
How ALT compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -12.8% is the 4th highest of 9, against a peer median of -16.1%.
- Research & development amounts to 185483.3% of revenue for ALT, versus a peer median of 131.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $446.24M USD | -15.0% | -3.0% | 681.3% | |
| LTM Jun 2026 | $294.44M USD | +79.9% | +83.9% | — | |
| LTM Mar 2026 | $91.32M USD | -20.8% | -13.4% | 131.9% | |
| FY2025 | €83.61M EUR | -8.0% | +11.4% | 1865.0% | |
| LTM Mar 2026 | $66.77M USD | -12.8% | -2.0% | 185483.3% | |
| LTM Mar 2026 | $64.86M USD | +10.1% | -2.5% | 91.2% | |
| LTM Mar 2026 | $48.2M USD | -55.0% | -0.4% | — | |
| LTM Mar 2026 | $20.4M USD | -57.1% | -33.1% | 10.7% | |
| LTM Mar 2026 | $7.02M USD | -17.1% | +13.9% | — | |
| Peer median (excluding ALT) | — | -16.1% | -1.5% | 131.9% | |
Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.41M | (68K) | 426K | 20K | 41K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 4.41M | (68K) | 426K | 20K | 41K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 74.54M | 70.54M | 65.8M | 82.23M | 66.43M |
| Selling, General & Admin | 15.41M | 17.13M | 18.14M | 20.97M | 28.1M |
| Operating Expenses | 101.32M | 87.67M | 96.36M | 103.19M | 94.53M |
| Depreciation & Amortization | 551K | 493K | 477K | 238K | 112K |
| EBITDA | (96.53M) | (84.41M) | (87.94M) | (94.81M) | (87.03M) |
| EBITDA Margin | -2189.0% | 124130.9% | -20642.0% | -474060.0% | -212258.5% |
| Operating Income | (96.91M) | (87.74M) | (95.93M) | (103.17M) | (94.49M) |
| Operating Margin | -2197.6% | 129029.4% | -22518.5% | -515860.0% | -230461.0% |
| Interest Income | 203K | 2.87M | 7.35M | 8.07M | 7.54M |
| Interest Expense | 5K | 8K | 35K | 9K | 1.64M |
| Other Income / Expenses | (176K) | 2.83M | 7.48M | 8.11M | 5.72M |
| Income Before Tax | (97.09M) | (84.91M) | (88.45M) | (95.06M) | (88.77M) |
| Pre-Tax Margin | -2201.6% | 124867.6% | -20762.2% | -475295.0% | -216522.0% |
| Income Tax Expense | 0 | (197K) | 0 | 0 | (681K) |
| Net Income | (97.09M) | (84.71M) | (88.45M) | (95.06M) | (88.09M) |
| Net Margin | -2201.6% | 124577.9% | -20762.2% | -475295.0% | -214861.0% |
| EPS (Basic) | (2.35) | (1.81) | (1.66) | (1.34) | (1.00) |
| EPS (Diluted) | (2.35) | (1.81) | (1.66) | (1.34) | (1.00) |
| Weighted Avg Shares | 41.28M | 46.93M | 53.25M | 71M | 88.1M |
| Weighted Avg Shares (Diluted) | 41.28M | 46.93M | 53.25M | 71M | 88.1M |
Altimmune, Inc.
NASDAQ:ALT
Intrinsic Alpha fair value
Locked
Current Price
$1.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.